Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Jun;66(6):727-31.
doi: 10.1136/ard.2006.061283. Epub 2006 Dec 15.

Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis

S M M Verstappen  1 , J W G Jacobs, D M van der Heijde, Sj van der Linden, C M Verhoef, J W J Bijlsma, A Boonen
Affiliations
Multicenter Study

Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis

S M M Verstappen et al. Ann Rheum Dis. 2007 Jun.

Abstract

Objectives: To compare utility and disease-specific direct costs between patients with ankylosing spondylitis (AS) and patients with rheumatoid arthritis (RA) in the Netherlands.

Methods: Patients with AS and those with RA completed questions on disease characteristics, the EuroQol-5D (EQ-5D) to assess utility, and questionnaire resource utilisation. Resource utilisation was assessed prospectively in AS, but retrospectively in RA. True cost estimates (2003) were used to calculate the costs. Differences in disease characteristics between AS and RA were described, and determinants of EQ-5D utility and costs were explored by Cox proportional hazard regressions.

Results: 576 patients with RA and 132 with AS completed the questionnaires. EQ-5D utility (0.63 vs 0.7) was lower, and annual direct costs higher in RA (euro5167 vs euro2574). In multivariate Cox proportional hazard regressions, there was no difference in utility between the diagnostic groups, but patients with RA incurred higher direct costs after controlling for age, gender and disease duration.

Conclusions: In patients with RA and patients with AS, who are under the care of a rheumatologist, utility is equally reduced, but healthcare costs are higher in RA after controlling for age, gender and disease duration. These data can be helpful to provide insights into the differences and similarities between the healthcare needs of both patient groups and to identify issues for further research and for policy in healthcare organisations.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 200027613–622. - PubMed
    1. Boonen A, van der Heijde D. Review of the costs of illness of ankylosing spondylitis and methodologic notes. Expert Rev Pharmacoecon Outcomes Res 20055163–181. - PubMed
    1. Cooper N J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 20003928–33. - PubMed
    1. Rosery H, Bergemann R, Maxion‐Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 200523243–257. - PubMed
    1. Garrett S, Jenkinson T, Kennedy L G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994212286–2291. - PubMed

Publication types